Status: Not yet recruiting
BV in the Treatment of Relapsed/refractory Hodgkin Lymphoma
The goal of this clinical trial is to explore the real-world Chinese relapsed/refractory patients to evaluate the efficacy and safety of BV monotherapy or combination therapy in CHL patients. The main questions it aims to answer are: To evaluate the efficacy and toxicity of BV-containing regimen in relapsed/refractory CHL patients in China, and to provide reference for the rational and safe use of BV in clinical practice.
Participants needed: 100
Trial details
Phase: Phase 4Age: 18+Biological sex: AllType: InterventionalSponsor: Xiuhua SunUpdated: Jan 7, 2025
Eligibility criteria
Histologically, classical hodgkin lymphoma（cHL） was diagnosed and relapsed or re... [+3]
<18 years